Recursion

Recursion has multiple clinical-stage programs, including REC-4881 in Phase 2, and reports clinical validation of its AI operating system plus repeated milestones with major pharma partners.

Recursion has multiple clinical-stage programs, including REC-4881 in Phase 2, and reports clinical validation of its AI operating system plus repeated milestones with major pharma partners.

Recursion operates an end-to-end AI-native drug discovery and development platform combining high-dimensional biology, automation, supercomputing and multimodal foundation models.

Recursion operates an end-to-end AI-native drug discovery and development platform combining high-dimensional biology, automation, supercomputing and multimodal foundation models.

Recursion operates an AI-native drug discovery engine integrating large-scale biological data generation, machine learning, chemistry, automation and supercomputing.

Recursion operates an AI-native drug discovery engine integrating large-scale biological data generation, machine learning, chemistry, automation and supercomputing.

Recursion uses multimodal machine learning, foundation models and large-scale biological data to drive target discovery, molecule design and clinical development.

Recursion uses multimodal machine learning, foundation models and large-scale biological data to drive target discovery, molecule design and clinical development.

Recursion combines clinical-stage drug development, strategic partnerships with Roche/Genentech, Sanofi and NVIDIA, a 50+ petabyte dataset and high-throughput experimentation at industrial scale.

Recursion combines clinical-stage drug development, strategic partnerships with Roche/Genentech, Sanofi and NVIDIA, a 50+ petabyte dataset and high-throughput experimentation at industrial scale.

The Recursion OS spans target identification through clinical trial enrollment, integrating data generation, models, laboratory automation and clinical workflows.

The Recursion OS spans target identification through clinical trial enrollment, integrating data generation, models, laboratory automation and clinical workflows.

ML, automation, data infrastructure and generative chemistry skills transfer broadly, while biology, chemistry and clinical-development specialization limit full cross-market portability.

ML, automation, data infrastructure and generative chemistry skills transfer broadly, while biology, chemistry and clinical-development specialization limit full cross-market portability.

Recursion and Valence Labs offer roles across machine learning, data science, engineering and computational biology, with research hubs in multiple North American and European cities.

Recursion and Valence Labs offer roles across machine learning, data science, engineering and computational biology, with research hubs in multiple North American and European cities.